As its next big bet, Sana inks long-term lease for manufacturing site for next-gen cell therapies
A unicorn multiple times over, Sana Biotechnology hit Nasdaq running in February with its next-gen cell therapies still months away from the clinic. Now, Sana is looking to the future once again and clearing out some elbow room for its manufacturing team.
Sana has entered a long-term lease to develop a 163,000-square-foot manufacturing facility in California to advance its late-stage clinical development and early commercial launches.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.